P. Andreotti

发表

Enzyme-linked immunomagnetic chemiluminescent detection of Escherichia coli O157:H7.

Shu-I Tu, Hashem Akhavan-Tafti, A. Gehring, 2004, Journal of immunological methods.

APPLICATIONS OF TIME‐RESOLVED FLUOROIMMUNOASSAY TO DETECT MAGNETIC BEAD CAPTURED ESCHERICHIA COLI O157:H7

Shu-I Tu, Peter L. Irwin, Linda S. L. Yu, 2001 .

Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)

Penny A. Johnson, I. Cree, L. Knight, 2009, BMC Cancer.

Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer

I. Cree, K. Müller, P. Andreotti, 1998, Anti-cancer drugs.

Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors

P. Andreotti, Xiao-yun Zhu, G. Caceres, 2003, Anti-cancer drugs.

Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.

I. Cree, P. Andreotti, H. Bruckner, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay.

I. Cree, J. Dewar, R. Wood, 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity.

I. Cree, D. Lane, P. Andreotti, 1994, Biochemical and biophysical research communications.

Serological and Cellular Recognition of Human Histocompatibility Antigens

P. Cresswell, P. Andreotti, M. Markert, 1981 .

HLA-A2 as a target for cell-mediated lympholysis: evidence from immunoselected HLA-A2 negative mutant cell lines.

P. Cresswell, P. Andreotti, J. Apgar, 1980, Human immunology.

Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro.

P. Andreotti, U. Wagner, D. Krebs, 1996, Cancer letters.

Heterogeneity ofin vitro chemosensitivity in perioperative breast cancer cells to mitoxantroneversus doxorubicin evaluated by a microplate ATP bioluminescence assay

I. Cree, P. Andreotti, D. Krebs, 2005, Breast Cancer Research and Treatment.

Chemosensitivity of normal human trophoblasts evaluated by a newly developed ATP-based luminescence assay

E. Wardelmann, I. Cree, A. Scharl, 2002, Anti-cancer drugs.

Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity

I. Cree, M. Untch, J. Dewar, 1996, Anti-cancer drugs.

In vitro activity of titanocenedichloride versus cisplatin in four ovarian carcinoma cell lines evaluated by a microtiter plate ATP bioluminescence assay

P. Andreotti, D. Krebs, H. Bruckner, 1995, Anti-cancer drugs.

Immunoassay of infectious agents.

Stephen S Morse, Leonard F Peruski, S. Morse, 2003, BioTechniques.

POTENTIATION OF ANTINEOPLASTIC COMPOUNDS BY ORAL DIMETHYL SULFOXIDE IN TUMOR‐BEARING RATS *

P. Andreotti, H. Jarosz, M. R. Sacksteder, 1975, Annals of the New York Academy of Sciences.

Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.

I. Cree, M. Untch, P. Andreotti, 1995, Cancer research.

Phorbol ester tumor promoter modulation of alloantigen-specific T lymphocyte responses.

P. Andreotti, 1982, Journal of immunology.

In vitro activity of titanocenedichloride versus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer.

P. Andreotti, D. Krebs, P. Mallmann, 1994, Anticancer research.

Human myeloid leukemic cell (HL-60) autostimulator: relationship to colony-stimulating factor.

S. K. Sinha, S. Perkins, P. Andreotti, 1984, Cancer research.

HLA control of interferon production in the human mixed lymphocyte culture.

P. Cresswell, P. Andreotti, 1981, Human immunology.

Heterogeneity of chemosensitivity of metastatic cutaneous melanoma.

U. Reinhold, I. Cree, R. MacKie, 1999, Anti-cancer drugs.

The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay.

I. Cree, P. Andreotti, E. Hunter, 1994, Anti-cancer drugs.

Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines.

I. Cree, P. Andreotti, I A Cree, 1997, Toxicology in vitro : an international journal published in association with BIBRA.

Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay.

I. Cree, M. Pazzagli, P. Andreotti, 1995, Anti-cancer drugs.

TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies.

I. Cree, M. Pazzagli, P. Andreotti, 1994, Journal of bioluminescence and chemiluminescence.

In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents.

P. Andreotti, W. Nagel, D. Krebs, 1994, Anticancer research.

THE USE OF TIME‐RESOLVED FLUOROIMMUNOASSAY TO SIMULTANEOUSLY DETECT ESCHERICHIA COLI O157:H7, SALMONELLA ENTERICA SEROVAR TYPHIMURIUM AND SALMONELLA ENTERICA SEROVAR ENTERIDITIS IN FOODS1

Shu-I Tu, Peter L. Irwin, Peter E. Andreotti, 2007 .

Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line.

P. Cresswell, D. Howell, P. Andreotti, 1985, Journal of immunology.

Imaging of luciferase and GFP-transfected human tumours in nude mice.

P. Andreotti, G. Caceres, Ralitza Zankina, 2003, Luminescence : the journal of biological and chemical luminescence.

Luminescence applications for chemotherapeutic drug development.

P. Andreotti, Peter E Andreotti, Gisela Caceres, 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.